Galiellalactone decreases the proportion of ALDH+ prostate cancer cells in vitro and the ALDH1A1 expression in vivo. by Rebecka Hellsten (348459)

“…The proportion of ALDH+ cells is expressed as mean ± SEM (n = 2–4). The proportion of ALDH+ DU145 cells were significantly decreased by galiellalactone at the concentrations 10 µM (p = 0.0060), 25 µM (p = 0,0013) and 50 µM galiellalactone (p<0,0001). …”

Length of whole blood clots from different amounts of blood in the in vitro middle cerebral artery model (diameter 3.1 mm). by Jan Víteček (11434774)

Chemical Inhibition of eEF1A-1 Peptide Elongation Activity Decreases Palmitate-Induced Cell Death. by Alexandra M. Stoianov (759321)

Tau phosphorylation is decreased in neurons treated with 20 mM KCl. by Nguyen-Vi Mohamed (323606)

“…<p>Immunoblot analysis of Tau phosphorylation in neurons treated either with 10mM or 20mM KCl. The phosphorylation of S199/S202, T181, T205 and S404 was not significantly affected by 10mM of KCl treatment whereas the phosphorylation of all these sites was decreased by 20mM of KCl treatment. …”

Decrease in extracellular Zn²⁺ in the hippocampus by zinc chelators. by Atsushi Takeda (18203)

PowerPoint Slides for: Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis by Bushinsky D.A. (3246690)

Combined EGCG/As decreases the viability of two types of EC, HUVEC and HBMEC. by Jee-Youn Kim (796526)

Sulpiride decreases anterior pituitary cell proliferation <i>in vivo</i>. by Jimena Ferraris (314722)

Calcium release from <i>S</i>. <i>mutans</i> at decreasing pHs. by Tarcísio Jorge Leitão (4811379)

5-FU induces a decrease in the total cell number in cultures of smooth muscle cells. by Marcelo de Carvalho Filgueiras (408321)

“…We found an initial reduction of 20% at 0.01 mM up to a reduction of 70% in 10 mM of 5-FU. At least 50 microscopic fields for each culture condition were scored in at least three independent experiments. …”

FSS rescues homocysteine-caused the decrease of NO production in cultured HUVECs after the application of A23187. by Cathy W. C. Bi (108697)

Effects of siRNA TMPRSS2-ERG III and IV on cell death pathways. by Giorgia Urbinati (554921)

Mean change in incidence and diagnoses if testing rates decrease. by Richard T. Gray (282417)

“…<p>Change in incidence (A) and diagnoses (B) if testing rates decrease by 30% and 50% relative to the current testing rate.…”

Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis by Raj Vuppalanchi (458660)

“…<div><p>Background and Aim</p><p>Liver cirrhosis is associated with decreased hepatic cytochrome P4503A (CYP3A) activity but the pathogenesis of this phenomenon is not well elucidated. …”

A typical GABA-MRS spectrum, where peaks of GABA, NAA, and combined glutamate and glutamine (Glx) are measured. by Hiroyuki Matsuta (13250169)

shRNA mediated silencing of CDK9 decreased proliferation of MM cells. by Su-Lin Lim (8997650)

TUNEL staining of testis tissues. by Cao Wang (1500691)

Subjects:

Oxidative stress (OS) responses in the testis tissues. by Cao Wang (1500691)

Subjects:

The prevalence of hypertension, diabetes, metabolic syndrome, cardiovascular disease and decreased GFR according to the following age groups: 60–69, 70–79 and ≥80 years. by Regina C. R. M. Abdulkader (302450)

“…Metabolic syndrome: presence of at least three of the following criteria: a waist circumference ≥90 cm for men or ≥80 cm for women, triglycerides ≥150 mg/dL, an HDL cholesterol ≤40 mg/dL for males or ≤50 mg/dL for females, a systolic blood pressure ≥130 mm Hg or a diastolic blood pressure ≥85 mmHg and a fasting plasma glucose ≥100 mg/dL. …”

Tempol and L-NAME help prevent the decrease in F_max. by Travis L. Dutka (321984)